

03/13/2007

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB number.

Substitute for form 1449A/PTO SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)		Complete if Known	
		Application Number	10/663,407
		Filing Date	September 15, 2003
		First Named Inventor	Zavitz et al.
		Art Unit	1648
		Examiner Name	J. Parkin
Sheet 1 of 1	Attorney Docket Number	1907-04-1X	

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
✓	1A	BISHOP et al., "Mammalian class E vps proteins recognize ubiquitin and act in the removal of endosomal protein-ubiquitin conjugates", <i>J Cell Bio.</i> , April 1, 2002, 157(1):91-101.	
↓	2A	LIU et al., "Overexpression of tumor susceptibility gene TSG101 in human papillary thyroid carcinomas", <i>Oncogene</i> , July 18, 2002, 21(31):4830-4837.	
	3A	SUN et al., "Tumor Susceptibility gene 101 protein represses androgen receptor transactivation and interacts with p300", <i>Cancer</i> , August 15, 1999, 86(4):689-696.	
	4A	XIE et al., "Cell cycle-dependent subcellular localization of the TSG101 protein and mitotic and nuclear abnormalities associated with TSG101 deficiency", <i>PNAS</i> , February 17, 1998, 95(4):1595-600.	
↓	5A	ZHONG et al., "Perturbation of TSG101 protein affects cell cycle progression", <i>Cancer Research</i> , July 1, 1998, 58(13):2699-26702.	

Examiner Signature	Date Considered	09/30/2007
--------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.